Ameritas Investment Partners Inc. Invests $1.88 Million in Elanco Animal Health Incorporated $ELAN

Ameritas Investment Partners Inc. bought a new stake in Elanco Animal Health Incorporated (NYSE:ELAN) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 93,129 shares of the company’s stock, valued at approximately $1,876,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Primecap Management Co. CA lifted its position in Elanco Animal Health by 3.1% in the second quarter. Primecap Management Co. CA now owns 51,766,814 shares of the company’s stock valued at $739,230,000 after purchasing an additional 1,543,279 shares during the period. Vanguard Group Inc. raised its stake in shares of Elanco Animal Health by 1.6% during the 3rd quarter. Vanguard Group Inc. now owns 48,586,708 shares of the company’s stock worth $978,536,000 after buying an additional 759,623 shares in the last quarter. Brandes Investment Partners LP raised its stake in shares of Elanco Animal Health by 11.3% during the 2nd quarter. Brandes Investment Partners LP now owns 8,100,322 shares of the company’s stock worth $115,673,000 after buying an additional 820,901 shares in the last quarter. Goldman Sachs Group Inc. lifted its holdings in shares of Elanco Animal Health by 104.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock valued at $50,268,000 after buying an additional 2,445,872 shares during the period. Finally, Jupiter Asset Management Ltd. boosted its stake in shares of Elanco Animal Health by 98.8% in the third quarter. Jupiter Asset Management Ltd. now owns 3,716,849 shares of the company’s stock valued at $74,857,000 after buying an additional 1,846,907 shares in the last quarter. 97.48% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have issued reports on ELAN. Wall Street Zen upgraded Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a research report on Monday, January 19th. Zacks Research cut shares of Elanco Animal Health from a “strong-buy” rating to a “hold” rating in a research note on Thursday, November 6th. UBS Group increased their price target on shares of Elanco Animal Health from $27.00 to $30.00 and gave the company a “buy” rating in a report on Thursday, January 29th. Piper Sandler upgraded shares of Elanco Animal Health from a “neutral” rating to an “overweight” rating and raised their price objective for the company from $24.00 to $30.00 in a research note on Thursday, January 22nd. Finally, Barclays began coverage on shares of Elanco Animal Health in a research report on Tuesday, December 9th. They set an “overweight” rating and a $30.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Elanco Animal Health presently has an average rating of “Moderate Buy” and a consensus price target of $27.22.

Elanco Animal Health Stock Performance

Shares of ELAN opened at $26.34 on Wednesday. Elanco Animal Health Incorporated has a 12-month low of $8.02 and a 12-month high of $26.87. The stock has a market cap of $13.09 billion, a P/E ratio of 439.11, a PEG ratio of 3.69 and a beta of 1.87. The company has a current ratio of 2.40, a quick ratio of 1.23 and a debt-to-equity ratio of 0.59. The company has a 50-day moving average of $23.97 and a two-hundred day moving average of $21.62.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings results on Tuesday, February 24th. The company reported $0.13 EPS for the quarter, beating the consensus estimate of $0.11 by $0.02. Elanco Animal Health had a net margin of 0.78% and a return on equity of 7.41%. The business had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.09 billion. During the same period in the prior year, the business earned $0.14 earnings per share. The company’s quarterly revenue was up 12.2% on a year-over-year basis. Elanco Animal Health has set its Q1 2026 guidance at 0.330-0.36 EPS and its FY 2026 guidance at 1.000-1.060 EPS. As a group, research analysts predict that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Lawrence Erik Kurzius purchased 10,000 shares of the business’s stock in a transaction dated Friday, December 12th. The stock was bought at an average cost of $21.30 per share, with a total value of $213,000.00. Following the completion of the acquisition, the director directly owned 131,773 shares in the company, valued at $2,806,764.90. The trade was a 8.21% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Robert M. Vanhimbergen acquired 6,950 shares of Elanco Animal Health stock in a transaction dated Thursday, December 11th. The stock was bought at an average price of $21.64 per share, for a total transaction of $150,398.00. Following the completion of the transaction, the chief financial officer directly owned 124,233 shares of the company’s stock, valued at approximately $2,688,402.12. This represents a 5.93% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last three months, insiders purchased 43,450 shares of company stock worth $937,883. 0.89% of the stock is currently owned by corporate insiders.

Key Elanco Animal Health News

Here are the key news stories impacting Elanco Animal Health this week:

• Positive Sentiment: Q4 beat on top- and bottom-line — Elanco reported adjusted EPS of $0.13 (vs. $0.11 est.) and revenue of $1.144B (above estimates), with revenue up ~12% year-over-year. Elanco Animal Health Reports Fourth Quarter and Full Year 2025 Results
• Positive Sentiment: Raised targets for innovation and product momentum — Elanco raised its 2026 innovation revenue target to $1.15B and highlighted delivery of the “Big 6” launches (including Befrena), supporting mid‑term growth expectations. Elanco Animal Health Reports Fourth Quarter and Full Year 2025 Results
• Positive Sentiment: Analyst upgrades/price target lifts — Leerink raised its price target to $30 with an outperform rating, adding buy-side support after the results. Leerink raises PT to $30 (Benzinga)
• Neutral Sentiment: FY‑2026 guidance roughly in line with Street — Elanco guided to adjusted EPS $1.00–$1.06 and revenue $4.95B–$5.02B (consensus ~ $1.03 EPS / $4.9B revenue), and Q1 EPS 0.33–0.36 (near consensus). That keeps 2026 growth narrative intact but leaves little upside surprise baked in. Elanco Sees Revenue Growth in 2026 (MarketWatch)
• Negative Sentiment: Margin pressure concerns weighed on sentiment — Several outlets flagged investor worry about near-term margin trends and adjusted EBITDA/margin trajectory, which capped upside despite the beats. That drove some intraday selling in parts of the tape. Elanco beats estimates but shares edge down on margin concerns (Investing.com)
• Negative Sentiment: GAAP loss and leverage remain watch points — The company reported a GAAP net loss and a net leverage ratio ~3.6x (targeting ~3.1–3.3x year‑end), which keeps balance‑sheet/credit risk and cash‑flow conversion on investors’ radar. Elanco Animal Health Reports Fourth Quarter and Full Year 2025 Results

Elanco Animal Health Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.